Quick Answer
ABVC BIOPHARMA, INC. reported R&D Expense of $121.1 thousand for fiscal year 2025.
ABVC BIOPHARMA, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $121.1K | -32.5% |
| 2024 | $179.3K | -83.1% |
| 2023 | $1.06M | -60.5% |
| 2022 | $2.69M | +168.3% |
| 2021 | $1.00M | +82.6% |
| 2020 | $549.7K | -47.6% |
| 2019 | $1.05M | +6.1% |
| 2018 | $988.7K | -68.8% |
| 2017 | $3.17M | +0.7% |
| 2017 | $3.15M | -68.5% |
| 2016 | $10.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.9K | -21.0% | -10.2% |
| June 30, 2025 | $33.3K | -17.6% | +15.3% |
| March 31, 2025 | $28.9K | -58.2% | -23.7% |
| September 30, 2024 | $37.8K | -73.2% | -6.4% |
| June 30, 2024 | $40.4K | -92.1% | -41.5% |
| March 31, 2024 | $69.1K | -79.4% | -51.1% |
| September 30, 2023 | $141.3K | -53.7% | -72.5% |
| June 30, 2023 | $514.4K | -3.4% | +53.6% |
- ABVC BIOPHARMA, INC. showed a decrease of -32.5% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, ABVC BIOPHARMA, INC.’s r&d expense has declined by 98.8% (from $10.00 million to $121.1 thousand).
- The most recent figure is from ABVC BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: